The EGFR-STYK1-FGF1 axis sustains functional drug tolerance to EGFR inhibitors in EGFR-mutant non-small cell lung cancer

Non-small cell lung cancer (NSCLC) patients harboring activating mutations in epidermal growth factor receptor (EGFR) are sensitive to therapy with EGFR tyrosine kinase inhibitors (TKI). Despite remarkable clinical responses using EGFR TKI, surviving drug tolerant cells serve as a reservoir from whi...

Descripción completa

Detalles Bibliográficos
Autores principales: Eggermont, Carolien, Giron, Philippe, Noeparast, Maxim, Vandenplas, Hugo, Aza-Blanc, Pedro, Gutierrez, Gustavo J., De Grève, Jacques
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9287553/
https://www.ncbi.nlm.nih.gov/pubmed/35840561
http://dx.doi.org/10.1038/s41419-022-04994-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9287553/
https://www.ncbi.nlm.nih.gov/pubmed/35840561
http://dx.doi.org/10.1038/s41419-022-04994-4

Ejemplares similares